Predictive and prognostic markers in the treatment of patients with solid tumors


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, immunotherapy is a leader in the treatment of disseminated melanoma, kidney cancer, pulmonary cancer, and is an option for the treatment of some solid tumors. However, in some cases, despite the improvement of clinical responses, immunotherapy is ineffective. The search for predictors of the immune response remains an urgent problem in modern antitumor therapy. This review demonstrates the results of studies describing the possibility of using a number of predictive and prognostic markers with high efficiency in clinical practice.

Full Text

Restricted Access

About the authors

D. O Yurlov

N.N. Petrov National Medical Research Center of Oncology

Email: arschtritt95@mail.ru
Oncologist, Posgraduate Student at the Scientific Department 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. A Baldueva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

  1. Madorsky Rowdo F.P, Baron A., Urrutia M., Mordoh J. Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol. 2015;6:127. doi: 10.3389/fimmu.2015.00127.
  2. Romano E., Kusio-Kobialka M., Foukas P.G., et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015;112:6140-45. Doi: 10.1073/ pnas.14 1 7320112.
  3. Sharma P, et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707-23. Doi: 10.1016/j. cell.2017.01.017.
  4. Qin W, Hu L., Zhang X., et al. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Front. Immunol. 2019;10:2298. Doi: 10.3389/ fimmu.2019.02298.
  5. Patel S.P, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983.
  6. Особенности определения уровня экспрессии PD-L1 для различных типов опухолей, онкологический конгресс. [Features of determining the level of expression of PD-L1 for various types of tumors, oncological congress. (In Russ.)]. URL: https://www.oncopathology.ru/sobytiya/ event/kongress4/osobennosti-opredeleniya-uro vnya-ekspressii-pd-l1-dlya-razlichnyh-tipov-opuholey.pdf.
  7. Reck M., Rodrfguez-Abreu D., Robinson A.G., et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37:7:537-46. doi: 10.1200/JC0.18.00149.
  8. Tony Shu-kam Mok, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-30. doi: 10.1016/S0140-6736(18)32409-7.
  9. Davis A.A., Patel V.G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 2019;7:278. doi: 10.1186/s40425-019-0768-9.
  10. Kai Li, Haiqing Luo, Lianfang Huang, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell. Int. 2020;20:16. doi: 10.1186/s12935-019-1091-8.
  11. Arulananda S., Thapa B., Walkiewicz M., et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588-94. doi: 10.1016/j.jtho.2018.07.015.
  12. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterol. 2010;138(6):2073-87.e3. Doi: 10.1053/j. gastro.2009.12.064.
  13. Overman M.J., et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet. Oncology. 2017;18(9):1182-91. doi: 10.1016/S1470-2045(17)30422-9.
  14. Wu Yongfeng, Xu Jinming, Du Chengli, et al. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2019;9:1161. Doi: 10.3389/ fonc.2019.01161.
  15. Schrock A.B., et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096-103. Doi. org/10.1093/annonc/mdz134.
  16. Carbone D.P, et.al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376:2415-26. Doi: 10.1056/ NEJMoa1613493.
  17. Hellmann M.D., et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020-31. Doi: 10.1056/ NEJMoa1910231.
  18. Биомаркеры иммунотерапии. [Biomarkers of immunotherapy. (In Russ.)]. URL: https://www. foundationmedicine.com/genomic-testing/ immunotherapy-biomarkers.
  19. Chua W, Charles K., Baracos V., et al. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288-95. Doi: 10.1038/ bjc.2011.100.
  20. Lino-Silva L.S., Salcedo-Hernandez R.A., Garcfa-Perez L, et al. Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma. Melanoma Res. 2017;27(2):140-44. doi: 10.1097/CMR.0000000000000333.
  21. Koh C, Bhoo-Pathy N., Ng K., et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150-58. doi: 10.1038/bjc.2015.183.
  22. Templeton A.J., McNamara M.G., SEuga B., et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI: J Nat Cancer Inst. 2014;106(6):124. doi: 10.1093/jnci/dju124.
  23. Zubing Mei, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta Analysis of 66 cohort studies. May 2017. Cancer Treatment Reviews 58. Doi: 10.1016/j. ctrv.2017.05.005.
  24. Жуков Н.В., Зарецкий А.Р, Лукьянов С.А., Румянцев С.А. Исследование циркулирующей опухолевой ДНК (жидкая биопсия). Перспективы использования в онкологии. Онкогематология. 2014;9(4):28-36.
  25. Xiao Han, Junyun Wang, Yingli Sun, et al. Circulating Tumor DNA as Biomarkers for Cancer Detection. Genom Proteom Bioinform. 2017;15(2):59-72. doi: 10.1016/j.gpb.2016.12.004.
  26. Lee J.H., et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With AntiProgrammed Cell Death 1 Antibodies. JAMA. Oncol. 2018;4(5):717-21. Doi: 10.1001/ jamaoncol.2017.5332.
  27. Moding E.J., Liu Y., Nabet B.Y, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer. 2020;1:176-83. doi: 10.1038/s43018-019-0011-0
  28. Стенина М.Б., Царева Е.В., Жаров А.А., Тюляндин С.А. Инфильтрирующие опухоль лимфоциты: биологическая суть и клиническое значение при раке молочной железы. Российский онкологический журнал. 2016;21(1-2):92-100.
  29. Naito Y, Saito K., Shiiba K., et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-94.
  30. Taylor R.C., Patel A., Panageas K.S., et al. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869-75. doi: 10.1200/JC0.2006.08.9755.
  31. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. Doi: 10.1038/ nature13954.
  32. Farhood B., Najafi M., Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234(6):8509-21. doi: 10.1002/jcp.27782.
  33. Chaput N., Lepage P, Coutzac C., et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368-79. doi: 10.1093/annonc/mdx108.
  34. Семиглазова Т.Ю., Бриш Н.А., Галунова Т.Ю. и др. Роль кишечной микробиоты в формировании ответа на иммунотерапию злокачественных новообразований: состояние проблемы. Медицинский совет. 2018;10:128-33.
  35. Mohiuddin J.J., et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy, JNCI: J Nat Cancer Inst. 2020 Apr 15;djaa057. Doi: 10.1093/ jnci/djaa057.
  36. Dummer R., et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358-72. doi: 10.1016/S1470- 2045(20)30062-0.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies